MRNS - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Marinus Pharmaceuticals Inc. - MRNS | Benzinga
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ:MRNS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Marinus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 15, 2024, Marinus issued a press release entitled "Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial results." The press release disclosed ...